Singapore markets closed

Vincerx Pharma, Inc. (VINC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.8967-0.0333 (-3.58%)
At close: 04:00PM EDT
0.7436 -0.15 (-17.07%)
Pre-market: 07:09AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.9300
Open0.9200
Bid0.8748 x 200
Ask0.9016 x 200
Day's range0.8800 - 0.9300
52-week range0.6100 - 9.3720
Volume235,271
Avg. volume1,167,891
Market cap19.201M
Beta (5Y monthly)0.81
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants

    PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,000,000 shares of common stock, and (ii) to certain investors, pre-funded warrants to purchase up to an aggregate of 16,000,000 shares of common stock and accompanying common stock warrants to purchase up to an aggregate of 16,000,000

  • GlobeNewswire

    Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants

    PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying common stock warrants to purchase shares of its common stock. All of the shares, pre-funded warrants and common stock warrants in the proposed offe

  • GlobeNewswire

    Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024

    VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic (PK) data shows very little free payload in circulation, consistent with the favorable safety profile observed preclinically and clinically In preclinical studies, Vincerx’s next-generation effector chemistry improves the efficacy of two approved antibody-drug conjugates (ADCs), highlighting VersAptx™